Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs PNC Financial Services Group Inc. (The) Common Stock (PNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs PNC Financial Services Group Inc. (The) Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while PNC Financial Services Group Inc. (The) Common Stock trades at $212.28 (market cap $86.09B). The key difference: PNC Financial Services Group Inc. (The) Common Stock is far larger — about 88.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and PNC Financial Services Group Inc. (The) Common Stock pays a 3.71% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| MRVI | PNC | |
|---|---|---|
Market Cap | $977.37M | $86.09B |
Volume | 2,742,564 | 3,223,582 |
Sector | Health | Financials |
52-Week High | $9.00 | $256.97 |
52-Week Low | $2.83 | $178.37 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $1.08B | $143.07B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PNC trades at $219.48, down 0.8% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $23.08B in 2025, with net income of $6.94B and a robust net income margin of 31.06%. Analyst consensus is a Buy with a $276.13 price target, indicating significant upside potential from current levels.
The outlook for PNC is positive given its earnings momentum and attractive valuation (P/E of 12.09), though risks include regulatory scrutiny and net cash outflows from investing activities. The stock offers a dividend yield supported by recent increases, positioning it as a value opportunity in the financial sector amid current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About PNC Financial Services Group Inc. (The) Common Stock
PNC Financial Services Group is a financial services holding company. Its businesses include retail banking, corporate and institutional banking, and asset management.
Read more on PNC →
